Research Paper Volume 10, Issue 9 pp 2394—2406

Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder

Figure 2. Rolipram reverses metabolic disorders. (A) Body weight and (B) food intake in normal and presenile mice, with or without rolipram treatment. (C) Serum total cholesterol level and (D) hepatic adiponectin levels in rolipram-treated and untreated presenile mice.